You are here: Industry Insights > Market News > Granules India posts Q2 net profit at Rs 40 crore

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate

Neohesperidin

Advantame

Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench

Pharma and Food Grade, USP/FCC Neotame Sweetener E961

Trilobatin

Granules India posts Q2 net profit at Rs 40 crore

expressbpdNovember 10, 2017

Tag: granules , net profit , India

Favorites

Total income during the quarter under review stood at Rs 399.39 crore

Granules India has reported almost flat consolidated net profit at Rs 40.33 crore for the September quarter of the current fiscal.

The company had posted a net profit of Rs 40.82 crore during the same period of the previous fiscal, Granules India said in a regulatory filing.

Total income during the quarter under review stood at Rs 399.39 crore as against Rs 367.68 crore in the July-September quarter of the last fiscal.

"As our emerging business is taking shape to drive future business growth, our core business continues to deliver sustainable revenues," Krishna Prasad Chigurupati, CMD, Granules India said.

Previous:Nanoshells could deliver more chemo with fewer side effects

Next:Morepen Labs ties up with Vesale Pharma

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Granules India posts Q2 net profit at Rs 40 crore | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Diminazene aceturate and Phenazone and Vitamin B granules for injection

Diminazene aceturate and Phenazone granules for injection

Factory price polymorph polymer filler PCL Polycaprolactone pellets microspheres granular granules M

Evening Primrose Oil (OEM/ODM) | Evening Primrose Oil From India / natural Evening Prim rose Oil

Compound salvia miltiorrhiza granules (Containing extract of Salviae Miltiorrhizae Radix et Rhizoma

Hot Melt Extruder Machine Twin Screw Plastic Granules Making Machine Double-sxrew Extruder Pharmaceu

Potassium Chloride Granules in sachet 1g/6g, 1.5g/10g

1-bromo-3-chloro-5,5-dimethylhydantoin Granules BCDMH CAS NO. 32718-18-6

1,3-dichloro-5,5-dimethylhydantoin DCDMH Granules CAS 118-52-5

Indian Trum etflower Seed Extract

Granules India posts Q2 net profit at Rs 40 crore

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

You may likeMore>>

You may like
More>>